Entering text into the input field will update the search result below

BioPharmCatalyst news 7/8/10

Jul. 08, 2010 9:46 AM ETINFIQ, EYPT, ALIM
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


ALIM ($7.13) and PSDV ($3.16) announced today that following last week's NDA filing for Diabetic Macular Edema, a Marketing Authorization Application (MAA) had been filed in Europe for the approval of Iluvien. Unlike in the US, no definitive action date is given for approval.

PSDV develops tiny delivery products that are implanted and then provide sustained release of drugs.

PSDV's main product in its pipeline is Iluvien for the treatment of Diabetic Macular Edema (DMA). There is currently no approved drug for this indication where the current standard of care is laser treatment. This is a back of they eye condition and front of the eye treatments such as eye drops are of little use as they do not reach the back of the eye. PSDV offers to insert a device directly to the back of the eye. DME is the primary cause of vision loss of diabetes patients.

NDA was filed on June 29, 2010, with a request for a 6 month Priority Review. If granted, a PDUFA action date of December 29, 2010 is expected. The FDA is required to respond to the Priority Review request within 45 days or by August 13.

Read press release here

INFI announced today that It had formed a partnership with Intellikine, Inc for the development and commercialisation of Intellikine's portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K). The products at this stage a pre-clinical, with INK1197, for inflammatory diseases, expected to start clinical trials in 2011. INFI will pay an initial $13.5m and up to $25 million in success-based milestones for the development of two distinct product candidates (also PI3K) and up to $450 million in success-based milestones for the approval and commercialization of two distinct products. Read press release here

FDA Calendar available by clicking HERE


Disclosure: No positions

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You